Aprea Therapeutics (APRE) vs Enveric Biosciences (ENVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aprea Therapeutics is the larger company by market cap ($7.0 million vs $6.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | APRE | ENVB |
|---|---|---|
| Share price | $0.5582 | $1.52 |
| Market cap | $7.03M | $6.80M |
| 1-day change | -7.74% | +1.67% |
| EPS (TTM) | $-0.95 | $-13.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $13.25 |
| 52-week low | $0.548 | $1.17 |
| Distance from 52-week high | -66.97% | -88.53% |
| Analyst consensus | none | — |
| Avg. price target upside | +568.22% | — |
| Average volume | 277.08K | 103.09K |
| Shares outstanding | 12.59M | 4.48M |
| Employees | 8 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Healthcare · Biotechnology · 8 employees
About Enveric Biosciences
ENVB stock →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Healthcare · Biotechnology · 5 employees
APRE vs ENVB FAQ
Which is bigger, Aprea Therapeutics or Enveric Biosciences?
Aprea Therapeutics (APRE) is larger, with a market capitalization of $7.03M compared with $6.80M for Enveric Biosciences (ENVB).
Are Aprea Therapeutics and Enveric Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.